Besides stomach cancer, the FDA also raised a similar concern for PD-1 drugs in first-line esophageal squamous cell carcinoma ...
Innovent Biologics has made the case that its checkpoint inhibitor-cytokine fusion protein has a future in colorectal cancer.
SON-1010 is a targeted immune activation cancer therapy designed to turn ‘cold’ tumors ‘hot’Topline safety data of SB101 Phase 1 study expected ...